• Vision & goals
• Research
• Production
• Organization
• Management
• Department Directors
• Board of directors
• History

History

Oasmia's history goes back to a private research project within bio-organic chemistry initiated in 1990. The basic idea behind the project was to study the aging of the cell but became more focused on the task to create more effective cancer drugs with acceptable side effects compared to current treatment options. 

The company was founded under its present name in 1999.

During the period 2003/2004 most of the basic research was completed concerning the company´s oncology platform based on the excipient XR-17.  In the end of 2004, clinical trials were initiated on the company´s promising product Paclical^®.

Paclical^® is currently in clinical phase III.

In 2005, Oasmia Pharmaceutical was introduced on NGM Nordic MTF. The company had then moved to new facilities intended for in-house GMP-production. In the same year the subsidiary Qdoxx Pharma was acquired. During the same period the investments in Paclical^® continued. In 2006, the Company acquired 51 percent of GlucoGene Pharma in order to strengthen Oasmia's oncology research portfolio. 

Due to the excellent results with Paccal^® Vet in dogs, the new department Animal Health was formed in 2007. In the autumn of that year, Oasmia changed list from NGM Nordic to NGM Equity in order to provide private and institutional shareholders an improved opportunity to trade with the company's shares. In late 2007, Oasmia signed a distribution and licensing agreement with Orion Corporation, Finland, for Paclical® in the Nordic countries.

Clinical Phase III trials for Paclical® and Paccal® Vet were initiated in early 2008. At the end of the year, Oasmia expanded the cooperation with Orion for Paccal® Vet to cover all of Europe.

In 2009, Oasmia signed a distribution and licensing agreement with American Abbott Laboratories for Paccal® Vet in the U.S. and Canada. The same year Paclical® was granted Orphan Drug designation by the FDA for the treatment of ovarian cancer in the U.S.

In early 2010, clinical Phase I/II trials were initiated with Doxophos® Vet. In the spring of 2010, a distribution and licensing agreement was signed with Japanese Nippon Zenyaku Kogyo Co. Ltd. for Paccal® Vet in Japan. Later in the spring, positive Phase III results were presented for Paccal® Vet, Oasmia's product candidate closest to market approval.

In late June 2010, Oasmia changed stock exchange list from NGM Equity to NASDAQ OMX Stockholm. The change was performed in order to offer private and institutional shareholders a more suitable market place for trading with the Oasmia share. In the same period, the Company reported positive results from the international Phase III study with Paccal® Vet. The study is the largest study in the world within veterinary oncology to date.